Physician profile
Marcus Kauffman
NPI 1831201326
$2,261.09
in general payments reported to CMS, 2019-2025
32 companies · $643 in 2025
The $643 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $483 · 2021: $319 · 2022: $198 · 2023: $34.08 · 2024: $45.73 · 2025: $643.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $624 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.69 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $264.67 | 2019-2025 | Xtandi |
| Bayer Healthcare Pharmaceuticals INC. | $161.27 | 2019-2022 | |
| Pfizer INC. | $141.42 | 2019-2022 | |
| Antares Pharma, INC. | $130.60 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $104.25 | 2025 | Gemtesa, Orgovyx |
| Abbvie INC. | $101.59 | 2025 | |
| Amgen INC. | $100.23 | 2020-2021 | |
| Allergan, INC. | $96.12 | 2019-2020 | |
| Myovant Sciences INC. | $87.38 | 2021 | |
| Janssen Biotech, INC. | $86.69 | 2019-2020 | |
| Dendreon Pharmaceuticals LLC | $84.38 | 2020-2025 | Provenge |
| Telix Pharmaceuticals | $78.08 | 2025 | Illuccix |
| Ferring Pharmaceuticals INC. | $77.42 | 2019-2025 | Adstiladrin |
| Tolmar Pharmaceuticals, INC. | $70.78 | 2019-2021 | |
| Rochester Medical Corporation | $64.77 | 2020-2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $64.48 | 2020-2022 | |
| Boston Scientific Corporation | $58.87 | 2019-2025 | Axonics |
| Coloplast Corp | $58.80 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $57.80 | 2025 | |
| Urogen Pharma, INC. | $47.67 | 2020-2022 | |
| Laborie Medical Technologies Corp. | $45.73 | 2024 | Optilume Bph Drug Coated Balloon Catheter |
| Procept Biorobotics Corporation | $40.35 | 2019-2025 | |
| Medtronic USA, INC. | $39.64 | 2020 | |
| Convatec INC. | $31.86 | 2019-2023 | |
| Immunitybio, INC. | $24.36 | 2025 | |
| Myriad Genetic Laboratories, INC. | $23.62 | 2020 | |
| Axonics, INC. | $23.58 | 2020 | |
| Janssen Scientific Affairs, LLC | $22.73 | 2019 | |
| Endo Pharmaceuticals INC. | $20.40 | 2023 | Xiaflex |
| Endo USA, INC. | $18.51 | 2025 | Xiaflex, Aveed |
| Urovant Sciences INC | $17.21 | 2022 | |
| Dentsply Ih INC. | $15.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Kauffman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.